- Home
- TRIP vs VRDN Comparison
TRIP vs VRDN Comparison
Compare TRIP & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRIP
- VRDN
- Stock Information
- Founded
- TRIP 2000
- VRDN 2006
- Country
- TRIP United States
- VRDN United States
- Employees
- TRIP N/A
- VRDN N/A
- Industry
- TRIP Computer Software: Programming Data Processing
- VRDN Medical Specialities
- Sector
- TRIP Technology
- VRDN Health Care
- Exchange
- TRIP Nasdaq
- VRDN Nasdaq
- Market Cap
- TRIP 1.6B
- VRDN 1.6B
- IPO Year
- TRIP 2011
- VRDN N/A
- Fundamental
- Price
- TRIP $15.02
- VRDN $12.39
- Analyst Decision
- TRIP Hold
- VRDN Buy
- Analyst Count
- TRIP 14
- VRDN 14
- Target Price
- TRIP $17.50
- VRDN $36.82
- AVG Volume (30 Days)
- TRIP 2.5M
- VRDN 887.1K
- Earning Date
- TRIP 05-07-2025
- VRDN 05-06-2025
- Dividend Yield
- TRIP N/A
- VRDN N/A
- EPS Growth
- TRIP 115.16
- VRDN N/A
- EPS
- TRIP 0.37
- VRDN N/A
- Revenue
- TRIP $1,838,000,000.00
- VRDN $302,000.00
- Revenue This Year
- TRIP $6.27
- VRDN N/A
- Revenue Next Year
- TRIP $7.64
- VRDN $20,553.29
- P/E Ratio
- TRIP $40.65
- VRDN N/A
- Revenue Growth
- TRIP 1.44
- VRDN 4.86
- 52 Week Low
- TRIP $10.43
- VRDN $9.90
- 52 Week High
- TRIP $27.63
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- TRIP 68.56
- VRDN 42.19
- Support Level
- TRIP $12.46
- VRDN $11.76
- Resistance Level
- TRIP $13.06
- VRDN $13.63
- Average True Range (ATR)
- TRIP 0.53
- VRDN 0.75
- MACD
- TRIP 0.39
- VRDN -0.02
- Stochastic Oscillator
- TRIP 91.63
- VRDN 22.11
About TRIP TripAdvisor Inc.
Tripadvisor is the world's leading travel metasearch company. Its platform offers 1 billion reviews and information on several million accommodations, restaurants, experiences, airlines, and cruises. In 2024, 52% of revenue came from the company's core Brand Tripadvisor segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 46% of sales in 2024, and TheFork, its dining brand, represented 10% of revenue (about 8% of sales were intersegment, which are eliminated from consolidated revenue).
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.